Clinical Trial Update: Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study of itacitinib in combination with docetaxel for non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Itacitinib (itacitinib)

Snippet

Sponsor: Incyte Corporation | Conditions: NSCLC (Non-small Cell Lung Carcinoma) | Phase 2 | Status: TERMINATED